PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales

•Up to 40% of PBC patients display inadequate response to standard of care with UDCA.•Among new therapeutic targets under investigation in PBC, PPARs ligands present a very promising profile due to anti-inflammatory and metabolic effects.•PPARs improve symptoms and quality of life in PBC4. Safety issues on PPAR-agonists use needs further assessment, especially in patients with advanced fibrosis.